JB Chemicals Clears USFDA Inspection at Panoli Facility

JB Chemicals & Pharmaceuticals Ltd announced on Friday, March 14, that its API (Active Pharmaceutical Ingredient) manufacturing facility (D9) in Panoli, Gujarat, has successfully cleared a US Food and Drug Administration (USFDA) inspection with no observations.

Zero Observations from USFDA

The inspection, conducted from March 10 to March 13, 2025, concluded without any Form 483 being issued, reaffirming the company’s commitment to regulatory compliance and quality manufacturing.

“The company remains committed to producing quality products, embedding a quality culture across the organisation, and continuously investing in systems, processes, and training of its employees to maintain the highest standards of quality and compliance for all its markets,” JB Chemicals stated.

Q3 FY25 Financial Performance

For the third quarter of the fiscal year, JB Chemicals & Pharmaceuticals reported a 21.6% year-on-year (YoY) rise in net profit, reaching ₹162.5 crore compared to ₹133.6 crore in Q3 FY24. The company’s revenue from operations grew 14.1% to ₹963.5 crore from ₹844.5 crore in the corresponding period of the previous fiscal year.

At the operating level, EBITDA increased by 14.1% to ₹254.5 crore in Q3 FY25, compared to ₹223.1 crore in the year-ago period. The EBITDA margin remained steady at 26.4%, reflecting consistent operational efficiency. EBITDA refers to earnings before interest, tax, depreciation, and amortisation.

Stock Performance 

On March 17, 2025, JB Chemicals & Pharmaceuticals share price traded 0.52% higher at ₹1,525.95 at 11:37 AM (IST). JB Chemicals & Pharmaceuticals’ share price reached a 52-week high of ₹2,029.00, and a 52-week low of ₹1,434.85. As per BSE, the total traded volume for the stock stood at 3,853 shares with a turnover of ₹58.76 lakhs.

At the current price, JB Chemicals & Pharmaceuticals shares are trading at a price-to-earnings (P/E) ratio of 72.75x, based on its trailing 12-month earnings per share (EPS) of ₹8.66, and a price-to-book (P/B) ratio of 2.29, according to exchange data.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.